B
Barbara Savoldo
Researcher at University of North Carolina at Chapel Hill
Publications - 123
Citations - 9680
Barbara Savoldo is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Antigen & Chimeric antigen receptor. The author has an hindex of 42, co-authored 123 publications receiving 7434 citations. Previous affiliations of Barbara Savoldo include Center for Cell and Gene Therapy & Baylor College of Medicine.
Papers
More filters
Journal ArticleDOI
CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients
Barbara Savoldo,Carlos A. Ramos,Carlos A. Ramos,Enli Liu,Martha P. Mims,Michael J. Keating,George Carrum,George Carrum,Rammurti T. Kamble,Rammurti T. Kamble,Catherine M. Bollard,Catherine M. Bollard,Adrian P. Gee,Zhuyong Mei,Hao Liu,Bambi Grilley,Bambi Grilley,Cliona M. Rooney,Cliona M. Rooney,Helen E. Heslop,Malcolm K. Brenner,Gianpietro Dotti +21 more
TL;DR: The results demonstrate the superiority of CARs with dual signal domains and confirm a method of comparing CAR-modified T cells within individual patients, thereby avoiding patient-to-patient variability and accelerating the development of optimal T cell immunotherapies.
Journal ArticleDOI
Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15
Yang Xu,Ming Zhang,Carlos A. Ramos,April G. Durett,Enli Liu,Olga Dakhova,Hao Liu,Chad J. Creighton,Adrian P. Gee,Helen E. Heslop,Cliona M. Rooney,Barbara Savoldo,Gianpietro Dotti +12 more
TL;DR: CD19-redirected T cells expanded ex vivo using IL-2, and found that their in vivo expansion only correlated with the frequency within the infused product of a CD8(+)CD45RA(+)CCR7(+) subset, whose phenotype is closest to "T-memory stem cells."
Journal ArticleDOI
Design and development of therapies using chimeric antigen receptor-expressing T cells
TL;DR: The value of adding additional engineering features to CAR‐T cells, irrespective of their target, to render them better suited to function in the tumor environment, and the safety of these heavily modified cells may be maintained are shown.
Journal ArticleDOI
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.
Antonio Di Stasi,Biagio De Angelis,Cliona M. Rooney,Lan Zhang,Aruna Mahendravada,Aaron E. Foster,Helen E. Heslop,Helen E. Heslop,Malcolm K. Brenner,Malcolm K. Brenner,Gianpietro Dotti,Gianpietro Dotti,Barbara Savoldo +12 more
TL;DR: It is shown that forced expression of CCR4 by effector T cells enhances their migration to HL cells, and this approach may be of value in patients affected by HL.
Journal ArticleDOI
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study
Conrad Russell Y. Cruz,Kenneth P. Micklethwaite,Barbara Savoldo,Carlos A. Ramos,Sharon Lam,Stephanie Ku,Oumar Diouf,Enli Liu,A. John Barrett,Sawa Ito,Elizabeth J. Shpall,Robert A. Krance,Robert A. Krance,Rammurti T. Kamble,Rammurti T. Kamble,George Carrum,George Carrum,Chitra Hosing,Adrian P. Gee,Zhuyong Mei,Bambi Grilley,Helen E. Heslop,Helen E. Heslop,Cliona M. Rooney,Malcolm K. Brenner,Malcolm K. Brenner,Catherine M. Bollard,Catherine M. Bollard,Gianpietro Dotti +28 more
TL;DR: CD19.CAR-VSTs display antitumor activity and, because their number may be increased in the presence of viral stimuli, earlier treatment post-HSCT (when lymphodepletion is greater and the incidence of viral infection is higher) or planned vaccination with viral antigens may enhance disease control.